Oxidative stress biomarkers as predictors of cardiovascular disease

International Journal of Cardiology

Volumn 147, Issue 2, 2011, Pages 191-201

  Strobel, Natalie A ^a   Fassett, Robert G ^a,b   Marsh, Susan A ^c   Coombes, Jeff S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Lipid peroxidation; Myeloperoxidase; Ox LDL; Protein oxidation

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; LIPID HYDROPEROXIDE; MALONALDEHYDE; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MARKER; ENZYME SPECIFICITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; LIPID PEROXIDATION; MORBIDITY; MORTALITY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS;

EID: 79951958873     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.008     Document Type: Review

References (82)

1. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24. (Pubitemid 19101597)
3. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005-28.
4. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313-6. (Pubitemid 27355575)
5. Chiu D, Lubin B. Oxidative hemoglobin denaturation and RBC destruction: the effect of heme on red cell membranes. Semin Hematol 1989;26:128-35. (Pubitemid 19128332)
6. Halliwell B, Murcia MA, Chirico S, Aruoma OI. Free radicals and antioxidants in food and in vivo: what they do and how they work. Crit Rev Food Sci Nutr 1995;35: 7-20.
7. Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. Faseb J 1987;1:441-5.
8. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478. (Pubitemid 39302636)
9. Jialal I. Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein. Clin Chem 1998;44:1827-32. (Pubitemid 28368903)
10. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008;101:34D-42D.
11. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-81. (Pubitemid 27203762)
12. Heinecke JW, Li W, Daehnke III HL, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993;268:4069-77. (Pubitemid 23072943)
13. Ahmed E, Trifunovic J, Stegmayr B, Hallmans G, Lefvert AK. Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke 1999;30:2541-6.
14. Bayes B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 2006;21: 984-90.
15. Bayes B, Pastor MC, Bonal J, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003;18:106-12. (Pubitemid 36104485)
16. Braun S, Ndrepepa G, von Beckerath N, et al. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. Am Heart J 2005;150:550-6. (Pubitemid 41317628)
17. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S. Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. Atherosclerosis 2005;183:157-62. (Pubitemid 41416834)
18. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004;53:1068-73. (Pubitemid 38436620)
19. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-7. (Pubitemid 41099043)
20. Naruko T, Ueda M, Ehara S, et al. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 2006;26:877-83. (Pubitemid 43732166)
21. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999;48:1454-8. (Pubitemid 29297310)
22. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154: 2605-9. (Pubitemid 24362412)
23. Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004;174:343-7. (Pubitemid 38597092)
24. Shoji T, Fukumoto M, Kimoto E, et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002;62: 2230-7. (Pubitemid 35366180)
25. Uusitupa MI, Niskanen L, Luoma J, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:1236-42. (Pubitemid 26339710)
26. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 2004;256:413-20. (Pubitemid 39434378)
27. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006;47:2219-28. (Pubitemid 43795077)
28. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
29. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002;39:957-62. (Pubitemid 34234116)
30. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63. (Pubitemid 28016072)
31. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J AmColl Cardiol 2006;48:973-9.
32. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006;113:167-73. (Pubitemid 44648400)
33. George J, Harats D, Bakshi E, et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999;68:263-6. (Pubitemid 29301886)
34. Wilson PW, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis 2006;189:364-8. (Pubitemid 44740294)
35. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007;27:1788-95. (Pubitemid 47207175)
36. Tsimikas S, Brilakis ES, Lennon RJ, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2007;48:425-33. (Pubitemid 46220609)
37. Mayr M, Kiechl S, Tsimikas S, et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 2006;47:2436-43. (Pubitemid 43866376)
38. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5. (Pubitemid 37176448)
39. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
40. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99:1364-8. (Pubitemid 46686633)
41. Exner M, Minar E, Mlekusch W, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006;47:2212-8. (Pubitemid 43795075)
42. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006;48:59-68.
43. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 2007;93:826-31. (Pubitemid 46998982)
44. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007;53:874-81. (Pubitemid 46744243)
45. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65. (Pubitemid 47002189)
46. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49: 1993-2000. (Pubitemid 46734639)
47. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-102.
48. Stefanescu A, Braun S, Ndrepepa G, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008;155:356-60.
49. Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007;49:2364-70. (Pubitemid 46891707)
50. El-Bejjani D, Hazen SL, Mackay W, et al. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials 2008;9:207-11. (Pubitemid 351892875)
51. Michowitz Y, Kisil S, Guzner-Gur H, et al. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J 2008;10:884-8.
52. Tang WH, Katz R, Brennan ML, et al. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 2009;103:1269-74.
53. Salonen JT, Nyyssonen K, Salonen R, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997;95:840-5. (Pubitemid 27091523)
54. Mezzetti A, Zuliani G, Romano F, et al. Vitamin E and lipid peroxide plasma levels predict the risk of cardiovascular events in a group of healthy very old people. J Am Geriatr Soc 2001;49:533-7. (Pubitemid 32525022)
55. Walter MF, Jacob RF, Jeffers B, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004;44: 1996-2002. (Pubitemid 39473284)
56. Walter MF, Jacob RF, Bjork RE, et al. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol 2008;51:1196-202. (Pubitemid 351382096)
57. Woodward M, Croft KD, Mori TA, et al. Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci (Lond) 2009;116:53-60.
58. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47. (Pubitemid 40038043)
59. Semba RD, Ferrucci L, Sun K, et al. Oxidative stress is associated with greater mortality in older women living in the community. J Am Geriatr Soc 2007;55: 1421-5. (Pubitemid 47329247)
60. Palinski W, Yla-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-35. (Pubitemid 20178661)
61. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003;108:2107-12. (Pubitemid 37337587)
62. Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76:663-9. (Pubitemid 26388165)
63. Itabe H, Yamamoto H, Imanaka T, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996;37:45-53. (Pubitemid 26052618)
64. Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996;98:800-14. (Pubitemid 26349186)
65. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006;17: 502-9. (Pubitemid 44372680)
66. Tsimikas S. Measures of oxidative stress. Clin Lab Med 2006;26:571-90 v-vi.
67. Guerci B, Antebi H, Meyer L, et al. Increased ability of LDL from normolipidemic type 2 diabetic women to generate peroxides. Clin Chem 1999;45:1439-48. (Pubitemid 29418996)
68. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308-15. (Pubitemid 39304342)
69. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 2001;286:2136-42. (Pubitemid 34041599)
70. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871-8. (Pubitemid 43739399)
71. Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008;394:59-62.
72. Knight JA, Pieper RK, McClellan L. Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin Chem 1988;34:2433-8. (Pubitemid 19017243)
73. Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1990;15:129-35. (Pubitemid 20186835)
74. Lankin VZ, Konovalova GG, Tikhaze AK, Nezhdanova IB, Olfer'ev AM, Kukharchuk VV. Oxidation of plasma low-density lipoproteins from coronary patients with various forms of hypercholesterolemia. Bull Exp Biol Med 2003;136:42-5.
75. Zieden B, Kaminskas A, Kristenson M, et al. Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1999;19:967-71. (Pubitemid 29177344)
76. Wu T, Rifai N, Roberts II LJ, Willett WC, Rimm EB. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomark Prev 2004;13:1399-402. (Pubitemid 39071567)
77. Musiek ES, Yin H, Milne GL, Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 2005;40:987-94.
78. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
79. Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem 2007;40:1297-304. (Pubitemid 47562416)
80. Mueller T, Dieplinger B, Gegenhuber A, et al. Serum total 8-iso-prostaglandin F2alpha: a new and independent predictor of peripheral arterial disease. J Vasc Surg 2004;40:768-73. (Pubitemid 39311646)
81. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003;14:213-8. (Pubitemid 36578048)
82. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-6. (Pubitemid 27276771)